AU2019397511B2 - Sulcardine administration for treatment of acute atrial fibrillation - Google Patents

Sulcardine administration for treatment of acute atrial fibrillation

Info

Publication number
AU2019397511B2
AU2019397511B2 AU2019397511A AU2019397511A AU2019397511B2 AU 2019397511 B2 AU2019397511 B2 AU 2019397511B2 AU 2019397511 A AU2019397511 A AU 2019397511A AU 2019397511 A AU2019397511 A AU 2019397511A AU 2019397511 B2 AU2019397511 B2 AU 2019397511B2
Authority
AU
Australia
Prior art keywords
pharmaceutically acceptable
acceptable salt
compound
subject
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019397511A
Other languages
English (en)
Other versions
AU2019397511A1 (en
Inventor
Gary T. Elliott
Suzanne J. Romano
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Huyabio International LLC
Original Assignee
Huyabio International LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Huyabio International LLC filed Critical Huyabio International LLC
Publication of AU2019397511A1 publication Critical patent/AU2019397511A1/en
Assigned to HUYABIO INTERNATIONAL, LLC reassignment HUYABIO INTERNATIONAL, LLC Amend patent request/document other than specification (104) Assignors: HUYA BIOSCIENCE INTERNATIONAL, LLC
Application granted granted Critical
Publication of AU2019397511B2 publication Critical patent/AU2019397511B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2019397511A 2018-12-13 2019-12-12 Sulcardine administration for treatment of acute atrial fibrillation Active AU2019397511B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862779056P 2018-12-13 2018-12-13
US62/779,056 2018-12-13
US201962858324P 2019-06-06 2019-06-06
US62/858,324 2019-06-06
PCT/US2019/066003 WO2020123824A1 (en) 2018-12-13 2019-12-12 Sulcardine administration for treatment of acute atrial fibrillation

Publications (2)

Publication Number Publication Date
AU2019397511A1 AU2019397511A1 (en) 2021-07-22
AU2019397511B2 true AU2019397511B2 (en) 2025-08-21

Family

ID=69165588

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019397511A Active AU2019397511B2 (en) 2018-12-13 2019-12-12 Sulcardine administration for treatment of acute atrial fibrillation

Country Status (11)

Country Link
US (4) US11364223B2 (https=)
EP (1) EP3893870A1 (https=)
JP (1) JP2022514537A (https=)
KR (1) KR20210135990A (https=)
CN (1) CN113453677A (https=)
AU (1) AU2019397511B2 (https=)
CA (1) CA3123078A1 (https=)
IL (1) IL283931A (https=)
MX (1) MX2021006933A (https=)
WO (1) WO2020123824A1 (https=)
ZA (1) ZA202104166B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113453677A (zh) 2018-12-13 2021-09-28 沪亚生物国际有限责任公司 用于治疗急性心房颤动的舒卡定施用
SG11202108160YA (en) 2019-01-29 2021-08-30 Huya Bioscience International Llc Sulcardine salts
IL298907A (en) * 2020-06-12 2023-02-01 Huyabio Int Llc Administering sulcardin for the treatment of acute atrial fibrillation
CN114984004B (zh) * 2022-05-25 2023-09-12 扬州中宝药业股份有限公司 硫酸舒欣啶在制备抗脓毒症药物中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011062906A2 (en) * 2009-11-17 2011-05-26 Elliot Gary T Treatment of atrial fibrillation
WO2011062903A2 (en) * 2009-11-17 2011-05-26 Elliott Gary T Slow infusion of sulcardine and its salts

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1172908C (zh) 1999-12-10 2004-10-27 中国科学院上海药物研究所 N-取代苄基或苯基芳香磺酰胺化合物及其用途
CN1939298A (zh) 2005-09-29 2007-04-04 中国科学院上海药物研究所 硫酸舒欣啶固体和靶向制剂及其制备方法
JP5308333B2 (ja) 2006-06-30 2013-10-09 シグマ−タウ レア ディジージズ エスィアー Ｌ−アスパラギナーゼｉｉを産生する組換え宿主
EP2468869B1 (en) 2007-01-31 2015-03-18 Pfenex Inc. Bacterial leader sequences for increased expression
KR20130072201A (ko) 2010-03-30 2013-07-01 피페넥스 인크. 재조합 독소 단백질의 고수준 발현
KR102092225B1 (ko) 2014-04-30 2020-03-23 주식회사 엘지화학 고효율 분비능을 가지는 단백질 분비 인자 및 이를 포함하는 발현 벡터
CN107532190B (zh) 2014-12-01 2021-07-09 菲尼克斯公司 用于肽生产的融合伴侣
AU2016272089B2 (en) 2015-06-03 2021-02-18 Triastek, Inc. Dosage forms and use thereof
AU2017261372B2 (en) 2016-05-05 2019-02-14 Triastek, Inc. Controlled release dosage form
EP3573602A4 (en) 2017-01-26 2020-09-16 Triastek, Inc. DOSAGE FORMS OF CONTROLLED RELEASE AT SPECIFIC GASTROINTESTINAL SITES
CN113453677A (zh) 2018-12-13 2021-09-28 沪亚生物国际有限责任公司 用于治疗急性心房颤动的舒卡定施用
SG11202108160YA (en) 2019-01-29 2021-08-30 Huya Bioscience International Llc Sulcardine salts

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011062906A2 (en) * 2009-11-17 2011-05-26 Elliot Gary T Treatment of atrial fibrillation
WO2011062903A2 (en) * 2009-11-17 2011-05-26 Elliott Gary T Slow infusion of sulcardine and its salts

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JULLIA LEE ET AL: "Antifibrillatory actions of HBI-3000 in the conscious canine model of sudden cardiac death", THE FASEB JOURNAL, FEDERATION OF AMERICAN SOCIETIES FOR EXPERIMENTAL BIOLOGY, US, vol. 23, 1 April 2009 (2009-04-01) *

Also Published As

Publication number Publication date
IL283931A (en) 2021-07-29
AU2019397511A1 (en) 2021-07-22
MX2021006933A (es) 2021-09-30
US20250302805A1 (en) 2025-10-02
US20240115548A1 (en) 2024-04-11
US12357611B2 (en) 2025-07-15
WO2020123824A1 (en) 2020-06-18
CN113453677A (zh) 2021-09-28
US20200188357A1 (en) 2020-06-18
JP2022514537A (ja) 2022-02-14
CA3123078A1 (en) 2020-06-18
US11883380B2 (en) 2024-01-30
EP3893870A1 (en) 2021-10-20
US20220280480A1 (en) 2022-09-08
US11364223B2 (en) 2022-06-21
ZA202104166B (en) 2023-11-29
KR20210135990A (ko) 2021-11-16

Similar Documents

Publication Publication Date Title
US11883380B2 (en) Sulcardine administration for treatment of acute atrial fibrillation
US20110166220A1 (en) Dronedarone for the prevention of permanent atrial fibrillation
US8541464B2 (en) Treatment of atrial fibrillation
US8637566B2 (en) Slow infusion of sulcardine and its salts
US20040102361A1 (en) Pharmaceutical composition for the treatment of pulmonary arterial hypertension
US12465587B2 (en) Sulcardine administration for treatment of acute atrial fibrillation
US20110166221A1 (en) Use of dronedarone for the preparation of a medicament for use in the prevention of cardioversion
JP2004512376A (ja) 虚血性障害の処置用医薬品の製造のためのメラガトランの使用
RU2358732C2 (ru) Жидкие фармацевтические композиции, содержащие производные 3,7-диазабицикло(3,3,1)нонана, для лечения антиаритмических реакций
EA045624B1 (ru) Введение сулькардина для лечения острой фибрилляции предсердий
US20260041665A1 (en) J-Tp Protection
HK40061591A (en) Sulcardine administration for treatment of acute atrial fibrillation
HK1155668A (en) Dronedarone for the prevention of permanent atrial fibrillation
HK1176859A (en) Treatment of atrial fibrillation
HK1176859B (en) Treatment of atrial fibrillation

Legal Events

Date Code Title Description
HB Alteration of name in register

Owner name: HUYABIO INTERNATIONAL, LLC

Free format text: FORMER NAME(S): HUYA BIOSCIENCE INTERNATIONAL, LLC

FGA Letters patent sealed or granted (standard patent)